Literature DB >> 15007383

Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases.

Yumi Aoyama1, Joseph Avruch, Xian-Feng Zhang.   

Abstract

Nore1, a noncatalytic protein identified by its ability to bind selectively to active Ras, is most closely related in amino-acid sequence to the tumor suppressor RASSF1. Both are expressed predominantly as a longer (Nore1A/RASSF1A) and/or shorter (Nore1B/RASSF1C) polypeptide; all four polypeptides contain a Ras-association domain and bind, through their conserved carboxytermini, the proapoptotic protein kinases MST1 and MST2. Moreover, the expression of the longer polypeptide is downregulated in human tumor cell lines through promoter methylation (frequently for RASSF1A, less regularly for Nore1A). Forced expression of RASSF1A in several such lines (including the NSCLC line A549) has been shown to suppress tumorigenicity; herein we inquire whether Nore has growth inhibitory activity. Four tumor cell lines were tested, selected for their low expression of both Nore1A and Nore1B; the two NSCLC lines, A549 and NCI-H460, each have a mutant active Ras oncogene, whereas the two melanoma lines G361 and M14 each contain the constitutively active BRaf(V599E) oncogene and wild-type Ras. The expression of Nore1A or Nore1B suppresses colony formation by the A549 and G361 lines, as effectively in A549 as does RASSF1A; colony formation in the NCI-H460 and M14 lines is unaffected. Nore1A inhibits anchorage-independent growth by A549 cells and delays A549 progression through G1 without evidence of increased apoptosis. The growth suppressive action of Nore1A is largely unaffected by deletion of both the MST- and Ras-binding domains, as well as by mutation of the Nore1A zinc finger. Thus, Nore1 suppresses the growth of some tumor cell lines through as yet unidentified effectors, independent of Ras-like proteins or MST1/2. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007383     DOI: 10.1038/sj.onc.1207486

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

Review 1.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 2.  Intrinsic protein disorder in oncogenic KRAS signaling.

Authors:  Ruth Nussinov; Hyunbum Jang; Chung-Jung Tsai; Tsung-Jen Liao; Shuai Li; David Fushman; Jian Zhang
Journal:  Cell Mol Life Sci       Date:  2017-06-08       Impact factor: 9.261

3.  Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors.

Authors:  Chang Kyun Lee; Jin-Hee Lee; Min-Goo Lee; Seong-In Jeong; Tae-Kyu Ha; Min-Ju Kang; Byung-Kyu Ryu; Young Hwangbo; Jae-Jun Shim; Jae Young Jang; Kil Yeon Lee; Hyo Jong Kim; Sung-Gil Chi
Journal:  BMC Cancer       Date:  2010-10-22       Impact factor: 4.430

4.  A wortmannin-cetuximab as a double drug.

Authors:  R Adam Smith; Hushan Yuan; Ralph Weissleder; Lewis C Cantley; Lee Josephson
Journal:  Bioconjug Chem       Date:  2009-11       Impact factor: 4.774

5.  Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras.

Authors:  Maria Praskova; Andrei Khoklatchev; Sara Ortiz-Vega; Joseph Avruch
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

Review 6.  Rassf family of tumor suppressor polypeptides.

Authors:  Joseph Avruch; Ramnik Xavier; Nabeel Bardeesy; Xian-Feng Zhang; Maria Praskova; Dawang Zhou; Fan Xia
Journal:  J Biol Chem       Date:  2008-12-17       Impact factor: 5.157

7.  Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II.

Authors:  Benjamin Stieglitz; Christine Bee; Daniel Schwarz; Ozkan Yildiz; Anna Moshnikova; Andrei Khokhlatchev; Christian Herrmann
Journal:  EMBO J       Date:  2008-07-03       Impact factor: 11.598

8.  Ras regulates SCF(β-TrCP) protein activity and specificity via its effector protein NORE1A.

Authors:  M Lee Schmidt; Howard Donninger; Geoffrey J Clark
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

9.  NORE1A tumor suppressor candidate modulates p21CIP1 via p53.

Authors:  Diego F Calvisi; Howard Donninger; Michele D Vos; Michael J Birrer; Laura Gordon; Virna Leaner; Geoffrey J Clark
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

10.  Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL).

Authors:  Katy Hanlon; Claudius E Rudin; Lorna W Harries
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.